The manufacturer recommends an initial trastuzumab dose of 4 mg/kg i.v. over 90 minutes, followed by a weekly maintenance dose of 2 mg/kg i.v. administered over 30 minutes if the initial dose is well ...
FDA approval of a second strength for HERCESSI paves the way for Accord BioPharma to prepare to commercially launch its first biosimilar; several others are in active development DURHAM, N.C., Sept.
The recent FDA approval of Hercessi expands access to a treatment previously burdened by high costs. Hercessi joins the 5 other biosimilars already on the market. The FDA has approved Hercessi, a ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive long-term follow-up data from the pivotal, Phase III ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), the Breast International Group (BIG), Institut Jules Bordet Clinical Trials Support ...
HERCESSI™ becomes one of two trastuzumab biosimilars on preferred formulary placement, expanding patient access to more affordable HER2-targeted oncology therapies RALEIGH, N.C., Jan. 5, 2026 ...
Outcomes for patients with metastatic HER2-positive breast cancer have improved as a result of research helping health care providers to understand the mechanisms of the protein, which has led to the ...
One expert explained the common side effects at every line of treatment for metastatic HER2-positive breast cancer during the CURE® Educated Patient® Metastatic Breast Cancer Summit. There are side ...
In the HER2-low population, treatment with trastuzumab deruxtecan reduced the risk of disease progression or death by 38% compared with chemotherapy. The Food and Drug Administration (FDA) has ...
Please provide your email address to receive an email when new articles are posted on . Short-duration trastuzumab did not show noninferiority to long-duration trastuzumab overall. Certain patients ...
The median total clinic time was not significantly shorter for patients who received subcutaneous trastuzumab/pertuzumab than for those who received the intravenous ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results